NASDAQ: REPLReplimune Group Inc Stock
$11.58+0.36 (+3.21%)
Updated Jul 2, 2026
REPL Price
$11.58
Fair Value Price
$1.95
Market Cap
$972.08M
52 Week Low
$1.50
52 Week High
$13.24
P/E
-3.43x
P/B
5.85x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$313.94M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
1
Operating Cash Flow
-$280M
Beta
1.01
Next Earnings
Aug 6, 2026
Ex-Dividend
N/A
Next Dividend
N/A
REPL Overview
Replimune Group, Inc. is a biotechnology enterprise dedicated to pioneering oncolytic immuno-gene therapies aimed at treating various cancers. The company leverages its proprietary Immunotherapy platform to engineer and advance novel therapeutic candidates designed to activate the body's immune system against malignant cells. Its leading experimental drug, RP1, is a selectively replicating variant of the herpes simplex virus 1. This candidate is presently in Phase I/II clinical trials for a range of solid tumors and has also progressed to Phase II trials specifically for patients with cutaneous squamous cell carcinoma. Replimune is additionally developing RP2, an anti-CTLA-4 antibody-like protein, which is undergoing Phase I clinical assessment. Its purpose is to counteract the immune system's suppression often mediated by CTLA-4. Furthermore, RP3, also in Phase I clinical trials, is engineered to express immune-activating proteins that stimulate T cells. Established in 2015, Replimune Group, Inc. maintains its corporate headquarters in Woburn, Massachusetts.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine REPL's potential to beat the market
DSell
- Stocks with a Zen Rating of Sell (D) had an average loss of -6.47% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
REPL
Ranked#311 of 463
Ranked#311 of 463
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $10.29 | A | |
| $243.47 | A | |
| $15.61 | A |
Be the first to know about important REPL news, forecast changes, insider trades & much more!
REPL News
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how REPL scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
REPL ($11.58) is overvalued by 494.57% relative to our estimate of its Fair Value price of $1.95 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
REPL ($11.58) is not significantly undervalued (494.57%) relative to our estimate of its Fair Value price of $1.95 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
REPL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more REPL due diligence checks available for Premium users.
Valuation
REPL fair value
Fair Value of REPL stock based on Discounted Cash Flow (DCF)
Price
$11.58
Fair Value
$1.95
Overvalued by
494.57%
REPL ($11.58) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
REPL ($11.58) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
REPL is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
REPL price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-3.43x
Industry
17.59x
Market
8.54x
REPL price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
5.85x
Industry
5.6x
REPL is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
REPL's financial health
Profit margin
Revenue
$0.0
Net Income
-$73.2M
Profit Margin
0%
REPL's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$332.4M
Liabilities
$166.2M
Debt to equity
1
REPL's short-term assets ($279.12M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
REPL's short-term assets ($279.12M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
REPL's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
REPL's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$56.2M
Investing
$86.5M
Financing
$55.7M
REPL's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
REPL vs Biotech Stocks
Replimune Group Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.